Herpes Labialis in a 17-Year-Old Boy

Article

These extremely painful sores recently developed on the lips of a young man being treated for Hodgkin lymphoma. More details here.


Photo courtesy of Ted Rosen, MD

A 17-year-old man, who was being treated for Hodgkin lymphoma, presented for medical attention because of the presence of extremely painful “sores” on his lip. He also had newly developed palpable submandibular and submental lymphadenopathy.

What’s your next step?

Please add your comments below and click here for discussion.

Related Videos
Angela Nash, PhD, APRN, CPNP-PC, PMHS | Image credit: UTHealth Houston
Allison Scott, DNP, CPNP-PC, IBCLC
Joanne M. Howard, MSN, MA, RN, CPNP-PC, PMHS & Anne Craig, MSN, RN, CPNP-PC
Juanita Mora, MD
Natasha Hoyte, MPH, CPNP-PC
Lauren Flagg
Venous thromboembolism, Heparin-induced thrombocytopenia, and direct oral anticoagulants | Image credit: Contemporary Pediatrics
Jessica Peck, DNP, APRN, CPNP-PC, CNE, CNL, FAANP, FAAN
Sally Humphrey, DNP, APRN, CPNP-PC | Image Credit: Contemporary Pediatrics
Related Content
Infants born into a digital world: Are there developmental inequities based on exposure? | Image Credit: © cendeced - © cendeced - stock.adobe.com.

Infants born into a digital world: Are there developmental inequities based on exposure?

April 24th 2024
Article

Donna Hallas, PhD, PPCNP-BC, CPNP, PMHS, FAANP, FAAN, highlights the April 2024 issue of Contemporary Pediatrics.

Site Logo

Food Insecurity and the Dangers of Infant Formula Dilution

January 30th 2023
Podcast
First radioactive drug approved for patients 12 years and up with SSTR-positive GEP-NETs | Image Credit: © Calin - © Calin - stock.adobe.com.

First radioactive drug approved for patients 12 years and up with SSTR-positive GEP-NETs

April 23rd 2024
Article

The FDA has approved lutetium Lu 177 dotatate for pediatric patients with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors.

Demystifying Infant Formula

Demystifying Infant Formula

October 11th 2022
Podcast
CRL issued for pz-cel as potential recessive dystrophic epidermolysis bullosa treatment | Image Credit: © Araki Illustrations - © Araki Illustrations - stock.adobe.com.

CRL issued for pz-cel as potential recessive dystrophic epidermolysis bullosa treatment

April 23rd 2024
Article

Abeona's pz-cel is up for indicated use to treat patients with recessive dystrophic epidermolysis bullosa.

Pandemic's impact on early childhood development may have been minimal

Pandemic's impact on early childhood development may have been minimal

April 22nd 2024
Article

An assessment into development scores before, during and after the COVID-19 pandemic show children aged 0 - 5 years old may only had been minimally impacted in communication and problem-solving skills.

© 2024 MJH Life Sciences

All rights reserved.